|
1
|
Ma O, Cai WW, Zender L, Dayaram T, Shen J,
Herron AJ, Lowe SW, Man TK, Lau CC and Donehower LA: MMP13, Birc2
(cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate
with p53 deficiency in mouse osteosarcoma progression. Cancer Res.
69:2559–2567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson ME: Update on survival in
osteosarcoma. Orthop Clin North Am. 47:283–292. 2016. View Article : Google Scholar
|
|
3
|
Duchman KR, Gao Y and Miller BJ:
Prognostic factors for survival in patients with high-grade
osteosarcoma using the surveillance, epidemiology, and end results
(SEER) program database. Cancer Epidemiol. 39:593–599. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kedmi R, Veiga N, Ramishetti S, Goldsmith
M, Rosenblum D, Dammes N, Hazan-Halevy I, Nahary L,
Leviatan-Ben-Arye S, Harlev M, et al: A modular platform for
targeted RNAi therapeutics. Nat Nanotechnol. 13:214–219. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shaikh AB, Li F, Li M, He B, He X, Chen G,
Guo B, Li D, Jiang F, Dang L, et al: Present advances and future
perspectives of molecular targeted therapy for osteosarcoma. Int J
Mol Sci. 17:5062016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Papiol S, Arias B, Barrantes-Vidal N,
Guitart M, Salgado P, Catalán R and Fañanás L: Analysis of
polymorphisms at the tumor suppressor gene p53 (TP53) in
contributing to the risk for schizophrenia and its associated
neurocognitive deficits. Neurosci Lett. 363:78–80. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li J, Yang L, Gaur S, Zhang K, Wu X, Yuan
YC, Li H, Hu S, Weng Y and Yen Y: Mutants TP53 p.R273H and p.R273C
but not p.R273G enhance cancer cell malignancy. Hum Mutat.
35:575–584. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xie Y, Zhu S, Song X, Sun X, Fan Y, Liu J,
Zhong M, Yuan H, Zhang L, Billiar TR, et al: The tumor suppressor
p53 limits ferroptosis by blocking DPP4 activity. Cell Rep.
20:1692–1704. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bedi A and Mookerjee B: Biological
significance and molecular mechanisms of p53-induced apoptosis.
Apoptosis. 3:237–244. 1998. View Article : Google Scholar
|
|
10
|
Xie C, Wu B, Chen B, Shi Q, Guo J, Fan Z
and Huang Y: Histone deacetylase inhibitor sodium butyrate
suppresses proliferation and promotes apoptosis in osteosarcoma
cells by regulation of the MDM2-p53 signaling. Onco Targets Ther.
9:4005–4013. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou Y, Niu W, Luo Y, Li H, Xie Y, Wang H,
Liu Y, Fan S, Li Z, Xiong W, et al: p53/Lactate dehydrogenase A
axis negatively regulates aerobic glycolysis and tumor progression
in breast cancer expressing wild-type p53. Cancer Sci. 110:939–949.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen Z, Guo J, Zhang K and Guo Y: TP53
mutations and survival in osteosarcoma patients: A meta-analysis of
published data. Dis Markers. 2016:46395752016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Luo Y, Deng Z and Chen J: Pivotal
regulatory network and genes in osteosarcoma. Arch Med Sci.
9:569–575. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhao YX, Wang YS, Cai QQ, Wang JQ and Yao
WT: Up-regulation of HDAC9 promotes cell proliferation through
suppressing p53 transcription in osteosarcoma. Int J Clin Exp Med.
8:11818–11823. 2015.PubMed/NCBI
|
|
15
|
Wu J, Guo A, Li Q and Wang D:
Meta-analysis of clinical significance of p53 protein expression in
patients with osteosarcoma. Future Oncol. 13:1883–1891. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
17
|
Farh KK, Grimson A, Jan C, Lewis BP,
Johnston WK, Lim LP, Burge CB and Bartel DP: The widespread impact
of mammalian MicroRNAs on mRNA repression and evolution. Science.
310:1817–1821. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pasquinelli AE, Hunter S and Bracht J:
MicroRNAs: A developing story. Curr Opin Genet Dev. 15:200–205.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Jones KB, Salah Z, Del Mare S, Galasso M,
Gaudio E, Nuovo GJ, Lovat F, LeBlanc K, Palatini J, Randall RL, et
al: miRNA signatures associate with pathogenesis and progression of
osteosarcoma. Cancer Res. 72:1865–1877. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Qin L, Chen Y, Niu Y, Chen W, Wang Q, Xiao
S, Li A, Xie Y, Li J, Zhao X, et al: A deep investigation into the
adipogenesis mechanism: Profile of microRNAs regulating
adipogenesis by modulating the canonical Wnt/beta-catenin signaling
pathway. BMC Genomics. 11:3202010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo Y, Zi X, Koontz Z, Kim A, Xie J,
Gorlick R, Holcombe RF and Hoang BH: Blocking Wnt/LRP5 signaling by
a soluble receptor modulates the epithelial to mesenchymal
transition and suppresses met and metalloproteinases in
osteosarcoma Saos-2 cells. J Orthop Res. 25:964–971. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zang X, Li Q, Wang W, Zhou Y, Chen S and
Xiao T: miR-181a promotes the proliferation and metastasis of
osteosarcoma cells by targeting RASSF1A. Zhong Nan Da Xue Xue Bao
Yi Xue Ban. 41:789–795. 2016.in Chinese; Abstract available in
Chinese from the publisher. PubMed/NCBI
|
|
23
|
Zhu ZJ, Huang P, Chong YX, Kang LX, Huang
X, Zhu ZX and Nie L: MicroRNA-181a promotes proliferation and
inhibits apoptosis by suppressing CFIm25 in osteosarcoma. Mol Med
Rep. 14:4271–4278. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shao JL, Li ZZ, Wang L, Jiao GL, Zhou ZG
and Sun GD: microRNA-181b promotes migration and invasion of
osteosarcoma cells by targeting N-myc downstream regulated gene 2.
Nan Fang Yi Ke Da Xue Xue Bao. 36:321–326. 2016.In Chinese.
PubMed/NCBI
|
|
25
|
Wang W, Wang Z, Chen S, Zang X and Miao J:
Interleukin-1β/nuclear factor-κB signaling promotes osteosarcoma
cell growth through the microRNA-181b/phosphatase and tensin
homolog axis. J Cell Biochem. 120:1763–1772. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kaste SC, Pratt CB, Cain AM, Jones-Wallace
DJ and Rao BN: Metastases detected at the time of diagnosis of
primary pediatric extremity osteosarcoma at diagnosis: Imaging
features. Cancer. 86:1602–1608. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
McCarville MB, Kaste SC, Cain AM,
Goloubeva O, Rao BN and Pratt CB: Prognostic factors and imaging
patterns of recurrent pulmonary nodules after thoracotomy in
children with osteosarcoma. Cancer. 91:1170–1176. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nolan T, Hands RE and Bustin SA:
Quantification of mRNA using real-time RT-PCR. Nat Protoc.
1:1559–1582. 2006. View Article : Google Scholar
|
|
29
|
Liu ZB, Wang JA and Lv RQ: Downregulation
of long non-coding RNA DBH-AS1 inhibits osteosarcoma progression by
PI3K-AKT signaling pathways and indicates good prognosis. Eur Rev
Med Pharmacol Sci. 23:1418–1427. 2019.PubMed/NCBI
|
|
30
|
Zheng Y, Lv X, Wang X, Wang B, Shao X,
Huang Y, Shi L, Chen Z, Huang J and Huang P: MiR-181b promotes
chemoresistance in breast cancer by regulating Bim expression.
Oncol Rep. 35:683–690. 2016. View Article : Google Scholar
|
|
31
|
Hong B, van den Heuvel AP, Prabhu VV,
Zhang S and El-Deiry WS: Targeting tumor suppressor p53 for cancer
therapy: Strategies, challenges and opportunities. Curr Drug
Targets. 15:80–89. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhou J, Wu S, Chen Y, Zhao J, Zhang K,
Wang J and Chen S: microRNA-143 is associated with the survival of
ALDH1+CD133+ osteosarcoma cells and the
chemoresistance of osteosarcoma. Exp Biol Med (Maywood).
240:867–875. 2015. View Article : Google Scholar
|
|
33
|
Mack DH, Vartikar J, Pipas JM and Laimins
LA: Specific repression of TATA-mediated but not initiator-mediated
transcription by wild-type p53. Nature. 363:281–283. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Dickins RA, Hemann MT, Zilfou JT, Simpson
DR, Ibarra I, Hannon GJ and Lowe SW: Probing tumor phenotypes using
stable and regulated synthetic microRNA precursors. Nat Genet.
37:1289–1295. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mirza A, Wu Q, Wang L, McClanahan T,
Bishop WR, Gheyas F, Ding W, Hutchins B, Hockenberry T, Kirschmeier
P, et al: Global transcriptional program of p53 target genes during
the process of apoptosis and cell cycle progression. Oncogene.
22:3645–3654. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Spurgers KB, Gold DL, Coombes KR,
Bohnenstiehl NL, Mullins B, Meyn RE, Logothetis CJ and McDonnell
TJ: Identification of cell cycle regulatory genes as principal
targets of p53-mediated transcriptional repression. J Biol Chem.
281:25134–25142. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He L, Yao H, Fan LH, Liu L, Qiu S, Li X,
Gao JP and Hao CQ: MicroRNA-181b expression in prostate cancer
tissues and its influence on the biological behavior of the
prostate cancer cell line PC-3. Genet Mol Res. 12:1012–1021. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Yang L, Wang YL, Liu S, Zhang PP, Chen Z,
Liu M and Tang H: miR-181b promotes cell proliferation and reduces
apoptosis by repressing the expression of adenylyl cyclase 9 (AC9)
in cervical cancer cells. FEBS Lett. 588:124–130. 2014. View Article : Google Scholar
|
|
39
|
Liu Y, Uzair-Ur-Rehman, Guo Y, Liang H,
Cheng R, Yang F, Hong Y, Zhao C, Liu M, Yu M, et al: miR-181b
functions as an oncomiR in colorectal cancer by targeting PDCD4.
Protein Cell. 7:722–734. 2016. View Article : Google Scholar : PubMed/NCBI
|
